KYMR Overview
Upcoming Projects (KYMR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KYMR)
-
Third View: Discussing Kymera Therapeutic's Phase 1 results for KT-474, an orally bioavailable heterobifunctional degrader for hidradenitis suppurativa and atopic dermatitis patients.
Ticker: KYMR
Executed On: Dec 23, 2024 at 04:00 PM EST -
Second View: Discussing Kymera Therapeutic's Phase 1 results for KT-474, an orally bioavailable heterobifunctional degrader for hidradenitis suppurativa and atopic dermatitis patients.
Ticker: KYMR
Executed On: Dec 23, 2024 at 09:00 AM EST -
Discussing Kymera Therapeutic's Phase 1 results for KT-474, an orally bioavailable heterobifunctional degrader for hidradenitis suppurativa and atopic dermatitis patients.
Ticker: KYMR
Executed On: Dec 18, 2024 at 04:30 PM EST -
Discussing protein degraders in the oncology space
Tickers: ARVN, CCCC, NRIX, KYMR
Executed On: Jan 05, 2022 at 02:00 PM EST
Upcoming & Overdue Catalysts (KYMR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (KYMR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!